Disclosures: Carlos Alventosa-Mateu: Nothing to Disclose, Mara Dolores Ocete Mochn: Nothing to Disclose, Juan Catal Bauset: Nothing to Disclose, Javier Hernndez Felices: Nothing to Disclose, Juan Jos Urquijo Ponce: Nothing to Disclose, Mercedes Latorre Snchez: Nothing to Disclose, Inmaculada Castell Miralles: Nothing to Disclose, Concepcin Cardona Gimeno: Nothing to Disclose, Moiss Diago: Nothing to Disclose 564 ASSOCIATIONS BETWEEN BIOMARKERS AND MAGNETIC RESONANCE IMAGING-DERIVED ANALI SCORE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: ANALYSIS FROM THE PHASE 3 PRIMIS STUDY Michael Trauner 1 Jun Xu 2 Xiangyu Liu 3 Kaiyi Zhu 3 Xiaomin Lu 3 Sharlene Lim 3 William Barchuk 3 Lisa Boyette 3 Clare Tempany 4 Zachary Goodman 5 Atsushi Tanaka 6 Douglas Thorburn 7 Cynthia Levy 8 Christopher Bowlus 9 , 1 Medical University of Vienna, 2 Gilead Sciences, Inc., 3 Gilead Sciences Inc., 4 Brigham and Women's Hospital, Harvard University, 5 INOVA Fairfax Hospital, 6 Teikyo University School of Medicine, 7 Royal Free Hospital, 8 University of Miami, 9 University of California, Davis Background and Aim: Magnetic resonance cholangiopancreatography (MRCP) is the standard diagnostic method for patients with primary sclerosing cholangitis (PSC)
Business Tort and Fraud Claims Intentional Business Interference: Customer relationship disruption
It might cover GLP-1 drugs when theyre prescribed for weight loss, as it wouldnt have the same statutory prohibition that applies to Part D coverage
It plays a crucial role in regulating blood sugar levels and is often necessary when lifestyle changes and oral medications are insufficient for maintaining optimal glucose control
:max_bytes(150000):strip_icc()/Simple-7-Day-GLP-1-Friendly-Meal-Plan-for-Beginners-Created-by-a-Dietitian-69f3d02b6c2c41928135df7f0c417552.jpg)
